Dr Felix Dobbs is co-founder and COO of Broken String Biosciences (www.brokenstringbio.com). He is the inventor of Broken String's INDUCE-seq, a genome-wide DNA break-mapping platform designed to solve one of the most pressing translational bottlenecks in gene editing therapeutic development: the standardized characterization of editing off-targets. Since co-founding Broken String in 2021, he has raised $25M in funding to deliver INDUCE-seq to gene editing therapy developers in the US, Europe and Asia, addressing the regulatory scrutiny around unintended off-target edits that has become a defining challenge for the sector. He holds an AstraZeneca-sponsored PhD from Cardiff University which was focussed on developing genomic tools to characterize the off-target effects of CRISPR-Cas9.